Literature DB >> 25010067

An update on RNA interference-mediated gene silencing in cancer therapy.

Yi-Jie Ren1, Yi Zhang.   

Abstract

INTRODUCTION: Based on our previous review, this article presents the new progress in RNA interference (RNAi)-mediated gene silencing in cancer therapy, and reviews the hurdles and how they might be overcome. AREAS COVERED: RNAi-mediated gene silencing approaches have been demonstrated in humans, and ongoing clinical trials hold promise for treating cancer or providing alternatives to traditional chemotherapies. Here we describe the broad range of approaches to achieve targeted gene silencing for cancer therapy, discuss the progress made in developing RNAi as therapeutics for cancer and highlight challenges and emerging solutions associated with its clinical development. EXPERT OPINION: Although the field of RNAi-based cancer therapy is still an emerging one, we have yet to get solutions for overcoming all obstacles associated with its clinical development. The current rapid advances in development of new targeted delivery strategies and noninvasive imaging methods will be big steps to explore RNAi as a new and potent clinical modality in humans.

Entities:  

Keywords:  RNAi; cancer therapy; gene silencing; update

Mesh:

Substances:

Year:  2014        PMID: 25010067     DOI: 10.1517/14712598.2014.935334

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  7 in total

Review 1.  Transfection by cationic gemini lipids and surfactants.

Authors:  M Damen; A J J Groenen; S F M van Dongen; R J M Nolte; B J Scholte; M C Feiters
Journal:  Medchemcomm       Date:  2018-07-17       Impact factor: 3.597

2.  Demystifying the mechanistic and functional aspects of p21 gene activation with double-stranded RNAs in human cancer cells.

Authors:  Huan-Lei Wu; Sen-Mao Li; Jia Hu; Xiao Yu; Hua Xu; Zhong Chen; Zhang-Qun Ye
Journal:  J Exp Clin Cancer Res       Date:  2016-09-17

3.  Deciphering fact from artifact when using reporter assays to investigate the roles of host factors on L1 retrotransposition.

Authors:  Pamela R Cook; G Travis Tabor
Journal:  Mob DNA       Date:  2016-11-22

Review 4.  Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.

Authors:  Akanksha S Mahajan; Alexander H Stegh
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

5.  A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.

Authors:  Priya Kumthekar; Caroline H Ko; Tatjana Paunesku; Karan Dixit; Adam M Sonabend; Orin Bloch; Matthew Tate; Margaret Schwartz; Laura Zuckerman; Ray Lezon; Rimas V Lukas; Borko Jovanovic; Kathleen McCortney; Howard Colman; Si Chen; Barry Lai; Olga Antipova; Junjing Deng; Luxi Li; Serena Tommasini-Ghelfi; Lisa A Hurley; Dusten Unruh; Nitya V Sharma; Manoj Kandpal; Fotini M Kouri; Ramana V Davuluri; Daniel J Brat; Miguel Muzzio; Mitchell Glass; Vinod Vijayakumar; Jeremy Heidel; Francis J Giles; Ann K Adams; C David James; Gayle E Woloschak; Craig Horbinski; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2021-03-10       Impact factor: 17.956

6.  Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.

Authors:  Bo Tang; Zhigao Hu; Yang Li; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Songqing He
Journal:  Mol Med Rep       Date:  2015-11-06       Impact factor: 2.952

7.  CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.

Authors:  Xiao-Fang Wei; You-Fan Feng; Qiao-Lin Chen; Qi-Ke Zhang
Journal:  Cancer Cell Int       Date:  2018-07-09       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.